Rory Sheehan and Angela Hassiotis discuss how to optimise psychotropic medication for people with intellectual disabilities; the theme of their #RSMpsychotropics conference taking place in London today.
[read the full story...]
Murtada Alsaif considers a recent systematic review on the safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression.
[read the full story...]
Samei Huda highlights a recent RCT of antipsychotics (risperidone and haloperidol) versus placebo for symptoms of delirium in palliative care, which suggests we need non-drug alternatives for this group of patients.
[read the full story...]
Joanne Wallace summarises the recent Cochrane systematic review on risperidone versus placebo for schizophrenia, which concludes that the best available evidence does not show that the benefits of risperidone outweigh the harms.
[read the full story...]
Tracey Roberts examines whether a retrospective observational study accurately investigates the effectiveness of second and first generation antipsychotics.
[read the full story...]
John Baker looks at the 2-year follow-up results of a cluster RCT on the effectiveness of financial incentives to improve adherence to maintenance treatment with depot antipsychotics.
[read the full story...]
Elena Marcus presents a recent study that shows how older Australian men with bipolar disorder have an increased risk of dementia and early death.
[read the full story...]
A live blog published at the 22nd International Network for Psychiatric Nursing Research conference in Nottingham.
Written by John Baker, Lucy Brazener, Wendy Cross, Vanessa Garrity, Andrew Grundy, Cher Hallett, Ben Hannigan, Elaine Hanzak and Alan Simpson.
[read the full story...]
Caroline Struthers scrutinises a systematic review on the longitudinal course of behavioural and psychological symptoms of dementia.
[read the full story...]
Samei Huda mulls over a recent RCT on the effects of older and newer antipsychotics on quality of life in schizophrenia. The study finds a different result to the 10-year old CUTLASS trial; namely that second generation antipsychotics may be superior to first generation antipsychotics in terms of improving quality of life for people with schizophrenia.
[read the full story...]
